Euflexxa is a hyaluronic acid-based viscosupplement designed to treat pain associated with knee osteoarthritis (OA). One of the most common questions surrounding this treatment is: “Is Euflexxa a steroid?” The answer is no. Euflexxa contains sodium hyaluronate, not corticosteroids, and works primarily by supplementing the viscoelastic properties of synovial fluid within the knee.
Unlike corticosteroid injections, which are intended to reduce inflammation through pharmacological effects, Euflexxa provides a different therapeutic approach. Its hyaluronic acid formulation is injected directly into the knee joint to improve lubrication and cushioning and may help reduce pain and improve function over time.
The FDA identifies Euflexxa as an intra-articular hyaluronic acid medical device approved under a Premarket Approval (PMA) pathway for pain associated with knee osteoarthritis.
In this article, we examine whether Euflexxa is a steroid, how it differs from corticosteroid injections, its mechanism of action, safety considerations, and its potential role in long-term knee OA management.
Key Takeaways
Euflexxa is not a steroid. It is an intra-articular hyaluronic acid product containing 1% sodium hyaluronate.
Euflexxa works differently from corticosteroids, primarily supporting the lubricating and viscoelastic properties of synovial fluid.
The product is FDA-approved for the treatment of pain associated with osteoarthritis of the knee in patients who have not responded adequately to conservative treatment and simple analgesics.
Euflexxa is administered as an intra-articular injection, with the approved regimen consisting of weekly injections over three weeks.
Common adverse events associated with Euflexxa include joint pain, swelling, joint effusion, and injection-site discomfort.
Corticosteroids and hyaluronic acid injections have different mechanisms, onset profiles, and clinical considerations.
Euflexxa should not be presented as a replacement for corticosteroids in every patient; treatment selection depends on disease severity, symptoms, medical history, and clinician judgment.
The FDA’s clinical data found a statistically significant improvement in knee pain at 26 weeks compared with saline in the pivotal study.
What Is Euflexxa and Is It a Steroid?
The simplest answer is no—Euflexxa is not a corticosteroid medication.
Euflexxa contains sodium hyaluronate, a form of hyaluronic acid, and is administered directly into the knee joint. The FDA describes the product as an intra-articular hyaluronic acid device indicated for treating pain associated with knee osteoarthritis.
Corticosteroids, by comparison, are anti-inflammatory drugs that act through pharmacological pathways to suppress inflammatory activity. Examples include medications such as triamcinolone and methylprednisolone.
The distinction is important because the two approaches address osteoarthritis symptoms in fundamentally different ways.
Euflexxa vs Corticosteroids at a Glance
Feature Euflexxa Corticosteroid Injection
Product type Hyaluronic acid viscosupplement Anti-inflammatory medication
Active component Sodium hyaluronate Corticosteroid
Steroid content None Yes
Primary action Lubrication and viscoelastic support Inflammation suppression
Administration Intra-articular Usually intra-articular
Onset Generally gradual Often faster
Main indication Knee OA pain Inflammatory arthritis/OA symptom flares
Systemic exposure Primarily local Can produce systemic steroid effects
Treatment strategy Often considered for longer-term symptom management Often used for short-term flare control
How Euflexxa Works in the Knee
Healthy synovial fluid contains hyaluronic acid, which contributes to the joint’s lubrication and shock-absorbing properties. Osteoarthritis can alter the quantity and quality of hyaluronic acid within the joint environment.
Euflexxa introduces sodium hyaluronate into the knee to supplement these properties.
1. Lubrication
Hyaluronic acid contributes to the viscous properties of synovial fluid. Supplementation can help improve the lubrication of articulating joint surfaces.
2. Shock Absorption
The viscoelastic characteristics of hyaluronic acid allow it to contribute to the cushioning of the joint during weight-bearing activities.
3. Support for Mobility
By improving the physical properties of joint fluid, viscosupplementation may help patients experience less discomfort during activities such as walking, standing, and climbing stairs.
4. Local Rather Than Systemic Treatment
Euflexxa is injected directly into the affected knee. This distinguishes it from medications administered systemically and means its intended action is concentrated within the joint.
The FDA’s clinical evaluation found that patients receiving three weekly Euflexxa injections demonstrated a statistically significant reduction in pain during the 50-foot walk test at 26 weeks compared with saline.
Euflexxa vs Corticosteroids: Different Treatment Strategies
Although both treatments may be used for knee pain, their therapeutic principles are different.
Euflexxa: Viscosupplementation
Euflexxa is intended to supplement the hyaluronic acid environment of the knee. Its primary role is associated with:
Joint lubrication
Viscoelastic support
Shock absorption
Improved joint fluid properties
Potential improvement in pain and function over time
It is therefore better understood as a viscosupplement rather than an anti-inflammatory steroid treatment.
Corticosteroids: Anti-Inflammatory Therapy
Corticosteroid injections work primarily through suppression of inflammatory processes. They may be particularly useful when a patient has a pronounced inflammatory flare and needs relatively rapid symptom relief.
However, the potential benefits and risks of repeated corticosteroid injections should be evaluated individually. The decision should take into account factors such as injection frequency, disease severity, comorbidities, and alternative treatment options.
Mechanical and Biological Effects of Hyaluronic Acid
The traditional explanation of viscosupplementation focuses on the mechanical role of hyaluronic acid.
However, research has also explored potential biological interactions between hyaluronic acid and cells within the joint.
These effects may include interactions with receptors such as CD44 and modulation of inflammatory signaling. However, these proposed biological mechanisms should not be interpreted as meaning that Euflexxa functions like a corticosteroid.
The most established clinical distinction remains that Euflexxa is an intra-articular hyaluronic acid viscosupplement, while corticosteroids are pharmacological anti-inflammatory agents.
Euflexxa Safety Profile
Safety is an important consideration when comparing viscosupplementation with other injection-based treatments.
According to FDA product information, adverse events reported in clinical studies of Euflexxa included:
Arthralgia
Joint swelling
Joint effusion
Injection-site pain
Musculoskeletal pain
Pain in an extremity
As with any intra-articular injection, clinicians should use appropriate aseptic technique and assess the patient for contraindications or potential complications.
Euflexxa should not be used in patients with known hypersensitivity to hyaluronate preparations, and injections should be avoided in the presence of infection in the joint or at the injection site.
Does Euflexxa Have the Same Risks as Steroid Injections?
Because Euflexxa does not contain corticosteroids, it does not have the same pharmacological mechanism or steroid-specific systemic effects.
That does not mean that Euflexxa is completely risk-free. Local reactions such as pain and swelling can occur, and intra-articular injections carry procedure-related risks.
Likewise, corticosteroids can be clinically useful but require careful consideration when injections are repeated over time.
Therefore, the question should not simply be “Which injection is safer?” Instead, clinicians should consider:
The patient’s diagnosis
Severity of osteoarthritis
Presence of inflammation
Previous injection response
Other medical conditions
Treatment goals
Frequency of previous injections
Potential adverse effects
Patient preference
Euflexxa Injection Schedule
The FDA-approved Euflexxa regimen consists of three weekly intra-articular injections. The product is supplied as a 1% sodium hyaluronate formulation.
Treatment Factor Euflexxa
Active component 1% sodium hyaluronate
Treatment area Knee joint
Administration Intra-articular
Schedule Once weekly for 3 weeks
Total injections 3
Steroid included No
FDA status PMA-approved medical device
Treatment should be administered by an appropriately qualified healthcare professional according to the current product labeling and clinical circumstances.
When Might Euflexxa Be Considered?
Euflexxa may be considered for patients with knee osteoarthritis who continue to experience pain despite conservative measures.
The FDA indication specifies patients whose symptoms have not responded adequately to conservative non-pharmacological treatment and simple analgesics such as acetaminophen.
A clinician may consider factors such as:
Persistent knee pain
Functional limitations
Previous response to conservative therapy
Patient tolerance of other treatments
Desire for a non-steroid injection option
Overall treatment goals
It is important to emphasize that viscosupplementation does not reverse the structural progression of osteoarthritis and is not appropriate for every patient.
Euflexxa vs Corticosteroid: Which Is Better?
There is no universal answer.
Corticosteroid injections may be useful when rapid reduction of inflammatory symptoms is the priority. Euflexxa, meanwhile, offers a different approach based on hyaluronic acid supplementation and mechanical support of the joint environment.
For some patients, clinicians may consider different injection strategies at different stages of treatment rather than viewing the two options as direct substitutes.
The appropriate choice depends on the individual’s symptoms, treatment history, risk factors, and clinical goals.
Conclusion
So, is Euflexxa a steroid? No.
Euflexxa is an intra-articular hyaluronic acid viscosupplement containing sodium hyaluronate, not a corticosteroid. Its purpose is to supplement the physical properties of synovial fluid and support lubrication and cushioning within the osteoarthritic knee. The FDA has approved Euflexxa through the PMA pathway for treatment of knee OA pain in appropriately selected patients.
Corticosteroid injections work through a different mechanism, primarily targeting inflammation, and may provide faster symptom relief in some circumstances. Euflexxa generally represents a different treatment strategy and should be selected according to the patient’s clinical situation rather than simply being viewed as a steroid alternative.
For healthcare professionals, understanding the differences between hyaluronic acid viscosupplementation and corticosteroid injections can support more informed treatment planning and patient counseling.
